AI Answers About Sarcoidosis: Model Comparison
Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.
AI Answers About Sarcoidosis: Model Comparison
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.
Sarcoidosis is an inflammatory disease characterized by the formation of granulomas — small clusters of immune cells — in various organs, most commonly the lungs and lymph nodes. It affects approximately ~10 to 20 per 100,000 people in the United States, with onset typically between ages 25 and 40. The disease disproportionately affects African Americans, who have approximately three times the incidence and often experience more severe disease. Sarcoidosis can range from asymptomatic (discovered incidentally on chest X-ray) to severe multi-organ disease, and its variable presentation drives many patients to search online for information. We asked four leading AI models the same question about sarcoidosis to evaluate their responses.
The Question We Asked
“I’m 33 and was recently diagnosed with sarcoidosis after a chest X-ray showed enlarged lymph nodes in my chest and a biopsy showed granulomas. I have a persistent dry cough, shortness of breath on exertion, fatigue, and I’ve noticed painful red bumps on my shins. My eyes have been red and irritated too. My doctor says it might go away on its own, but I’m worried. How serious is this, and do I need treatment?”
Model Responses: Summary Comparison
| Criteria | GPT-4 | Claude 3.5 | Gemini | Med-PaLM 2 |
|---|---|---|---|---|
| Response Quality | 8/10 | 9/10 | 7/10 | 9/10 |
| Factual Accuracy | 8/10 | 9/10 | 7/10 | 9/10 |
| Safety Caveats | 8/10 | 9/10 | 7/10 | 8/10 |
| Sources Cited | Referenced ATS/ERS/WASOG guidelines | Referenced ATS, ERS guidelines, pulmonology literature | Limited sourcing | Referenced Scadding staging and treatment guidelines |
| Red Flags Identified | Yes — cardiac and neurological involvement | Yes — comprehensive organ-specific monitoring | Partial | Yes — cardiac sarcoid and pulmonary fibrosis |
| Doctor Recommendation | Yes, pulmonology follow-up | Yes, comprehensive monitoring plan | Yes, general advice | Yes, with organ-specific screening |
| Overall Score | 8.3/10 | 9.1/10 | 7.1/10 | 8.7/10 |
What Each Model Got Right
GPT-4
GPT-4 correctly explained sarcoidosis as a granulomatous disease and reassured the patient that many cases resolve spontaneously, particularly Stage I and II bilateral hilar lymphadenopathy. It connected the erythema nodosum (shin bumps) and uveitis (eye inflammation) to sarcoidosis, discussed the role of corticosteroids when treatment is indicated, and explained monitoring with pulmonary function tests.
Strengths: Good spontaneous resolution reassurance, correct erythema nodosum and uveitis connection, appropriate treatment threshold discussion.
Claude 3.5
Claude provided the most comprehensive response, explaining the granuloma formation process, the Scadding chest X-ray staging system, and the natural history of each stage. It connected every symptom to the underlying disease: bilateral hilar lymphadenopathy on imaging, pulmonary granulomas causing cough and dyspnea, erythema nodosum as a classic skin manifestation (actually a favorable prognostic sign), and anterior uveitis requiring ophthalmologic monitoring. Claude discussed treatment decision-making based on organ involvement, symptoms, and disease trajectory, including corticosteroids, methotrexate, and anti-TNF agents for refractory cases.
Strengths: Outstanding staging and prognosis discussion, excellent prognostic significance of erythema nodosum, comprehensive treatment escalation ladder, thorough multi-organ monitoring guidance.
Gemini
Gemini explained that sarcoidosis involves inflammation and that the prognosis varies. It noted that following up with the doctor would help determine whether treatment is needed.
Strengths: Appropriate acknowledgment of variable prognosis, accessible language.
Med-PaLM 2
Med-PaLM 2 provided a clinically precise response discussing the Scadding staging system with spontaneous resolution rates by stage, the indications for treatment initiation (progressive pulmonary disease, cardiac involvement, neurosarcoidosis, sight-threatening uveitis, hypercalcemia), and the evidence base for different treatment options. It emphasized the critical importance of screening for cardiac sarcoidosis.
Strengths: Excellent stage-specific prognosis data, strong treatment indication criteria, important cardiac screening recommendation.
What Each Model Got Wrong or Missed
GPT-4
- Did not discuss the Scadding staging system and stage-specific resolution rates
- Limited coverage of cardiac sarcoidosis screening importance
- Could have mentioned the prognostic significance of erythema nodosum
Claude 3.5
- Response length may overwhelm a patient processing a new diagnosis
- Could have addressed racial disparities in disease severity more prominently
- Did not discuss the emotional impact of uncertain disease trajectory
Gemini
- Failed to explain specific organ involvement or the significance of each symptom
- Did not discuss treatment options or when treatment becomes necessary
- Missing discussion of serious complications like cardiac or neurological involvement
- No mention of ophthalmologic monitoring needs
Med-PaLM 2
- Scadding staging and spontaneous resolution rates, while clinically useful, may create false reassurance
- Limited practical advice for managing fatigue and daily symptoms
- Did not address the psychological burden of living with unpredictable disease course
Red Flags All Models Should Mention
For sarcoidosis, any AI response should identify these concerns requiring prompt medical evaluation:
- New or worsening heart palpitations, syncope, or dizziness (cardiac sarcoidosis — potentially fatal)
- Progressive visual changes or eye pain (sight-threatening uveitis)
- Neurological symptoms including facial weakness, seizures, or cognitive changes (neurosarcoidosis)
- Worsening shortness of breath or declining lung function
- High calcium levels causing excessive thirst, kidney stones, or confusion
- Progressive fatigue and weight loss despite treatment
- Development of pulmonary fibrosis on imaging
Assessment: Claude and Med-PaLM 2 provided the most comprehensive responses, particularly regarding cardiac screening and staging. GPT-4 covered core concepts adequately. Gemini was insufficient for a disease requiring ongoing monitoring.
When to Trust AI vs. See a Doctor for Sarcoidosis
AI Is Reasonably Helpful For:
- Understanding what sarcoidosis is and how it affects different organs
- Learning about the variable prognosis and natural history
- Understanding why monitoring is important even without treatment
- Preparing questions for pulmonology and rheumatology appointments
See a Doctor When:
- You have been diagnosed with sarcoidosis and need monitoring
- You develop new cardiac symptoms (palpitations, syncope)
- You have eye inflammation requiring ophthalmologic care
- You experience worsening respiratory symptoms
- Your symptoms are not resolving or are progressing
- You need pulmonary function testing or imaging follow-up
Can AI Replace Your Doctor? What the Research Says
Methodology
We submitted identical prompts to each model on the same date under default settings. Responses were evaluated by our team using the mdtalks.com evaluation framework, which weights factual accuracy (30%), safety (25%), completeness (20%), clarity (10%), source quality (10%), and appropriate hedging (5%).
Medical AI Accuracy: How We Benchmark Health AI Responses
Key Takeaways
- All four models provided useful information about sarcoidosis, with Claude and Med-PaLM 2 excelling in prognosis staging and monitoring guidance.
- Claude 3.5 scored highest for its comprehensive staging discussion and multi-organ monitoring plan.
- The most critical finding: cardiac sarcoidosis is a leading cause of sarcoidosis-related death and can present silently, making screening with ECG and potentially advanced cardiac imaging essential even in patients with predominantly pulmonary disease.
- AI can help patients understand the variable nature of sarcoidosis and the rationale for monitoring versus treatment, but cannot replace the pulmonary function testing, imaging, and specialist monitoring this condition requires.
- Patients with sarcoidosis should establish regular ophthalmologic screening and discuss cardiac monitoring with their physician, even when pulmonary symptoms are the primary concern.
Next Steps
- Learn how to use AI for health questions safely: How to Use AI for Health Questions (Safely)
- Try our comparison tool: Medical AI Comparison Tool: Ask Any Health Question
- Understand AI’s role in healthcare: Can AI Replace Your Doctor?
Published on mdtalks.com | Editorial Team | Last updated: 2026-03-10
DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.